A Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients With Chronic Hepatitis C Virus (MAGELLAN-2)

NCT02692703 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Hepatitis C
HCV
Hepatitis C Virus

Interventions

DRUG: glecaprevir/pibrentasvir

Sponsor

AbbVie